Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company
focused on the discovery and development of CAR T cell therapies based on T lymphocytes (Chimeric Antigen Receptor)
for the treatment of cancer, today announced that the company will participate in the following conference virtually in February 2022:
Virtual 11th Annual SVB Leerink Global Healthcare Conference 2022
Dates: Monday, February 14 to Friday, February 18, 2022
Presentation: February 18 at 8:00 a.m. ET / 2:00 p.m. CET
Speaker: Filippo Petti, CEO
Webcast: A live webcast will be available in the Events section of the Celyad Oncology website.